Alliance Global Partners initiated coverage of CNS Pharmaceuticals (CNSP) with a Buy rating and $4 price target CNS is a clinical-stage ...
In a report released today, James Molloy from Alliance Global Partners initiated coverage with a Buy rating on CNS Pharmaceuticals (CNSP – ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...
2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's CNS and rare disease drug candidates, which will be discussed today during ...
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...
The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation.
Based on the one-year price targets offered by 2 analysts, the average target price for Cohen & Steers Inc (NYSE:CNS) is $95.50 with a high estimate of $100.00 and a low estimate of $91.00.
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.